Incannex Healthcare Inc. has announced the successful completion of its RePOSA Phase 2 clinical trial database lock for IHL-42X, a drug candidate aimed at treating obstructive sleep apnoea (OSA). This milestone, achieved on June 16, 2025, enables the commencement of final statistical analysis. The top-line results of the trial are expected to be released in July 2025. The trial focuses on patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). IHL-42X is being developed as a fixed-dose combination therapy designed to reduce apnea episodes and improve sleep quality, aiming to provide an alternative to current treatments in a field where no approved oral pharmacological treatments currently exist.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。